Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
2:48pm EST
Change (% chg)

$-0.00 (-1.66%)
Prev Close
$0.26
Open
$0.26
Day's High
$0.26
Day's Low
$0.25
Volume
123,052
Avg. Vol
177,749
52-wk High
$1.96
52-wk Low
$0.23

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $21.40
Shares Outstanding(Mil.): 81.02
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population

* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

Feb 12 2018

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

Feb 06 2018

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017

Dec 13 2017

BRIEF-Contravir Pharmaceuticals enters research collaboration with Li Ka Shing Institute of Virology

* Contravir Pharmaceuticals announces research collaboration agreement with Li Ka Shing Institute of Virology Source text for Eikon: Further company coverage: (Reporting by Sruthi Ramakrishnan)

Oct 17 2017

BRIEF-Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.

* Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States

Sep 11 2017

BRIEF-U.K. accepts Contravir Pharma's clinical trial application

* Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom

Sep 06 2017

Earnings vs. Estimates